Sarepta Therapeutics’ (SRPT) “Underperform” Rating Reaffirmed at JMP Securities
JMP Securities reissued their underperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report published on Thursday. The brokerage currently has a $10.00 price objective on the stock.
A number of other research analysts have also weighed in on the company. Cowen and Company restated a market perform rating on shares of Sarepta Therapeutics in a research report on Monday, August 15th. Jefferies Group restated an underperform rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 25th. Robert W. Baird restated an outperform rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Vetr upgraded Sarepta Therapeutics from a sell rating to a hold rating and set a $17.28 price objective for the company in a research report on Monday, June 20th. Finally, Needham & Company LLC raised their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a buy rating in a research report on Friday, July 22nd. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Thursday. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $56.80. The stock has a 50 day moving average price of $28.17 and a 200 day moving average price of $21.37. The company’s market cap is $2.67 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. Analysts anticipate that Sarepta Therapeutics will post ($4.98) earnings per share for the current fiscal year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.90% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC bought a new position in Sarepta Therapeutics during the second quarter valued at $335,000. Schwab Charles Investment Management Inc. increased its position in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock valued at $2,934,000 after buying an additional 2,766 shares during the period. Stifel Financial Corp increased its position in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock valued at $441,000 after buying an additional 1,178 shares during the period. American Century Companies Inc. bought a new position in Sarepta Therapeutics during the second quarter valued at $651,000. Finally, First Allied Advisory Services Inc. increased its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.